CC-Thrombis-Day3

Apixaban inhibits factor ___and acts as an anticoagulant and prevents formation of new clot and inhibits increase in size of existing clot.

• IIa

• Ia

• Va

• Xa

Recommended dose of Apixaban in NVAF patients with creatinine clearance greater than 50 ml/minute is ___mg twice daily for life long.

• 2.5

• 5

• 10

• None of these

Recommended dose of Apixaban in NVAF patients with creatinine clearance between 15 to 29 ml/minute is ___mg twice daily for life long.

• 2.5

• 5

• 10

• None of these

Recommended dose of Apixaban in DVT/PE treatment patients with creatinine clearance greater than 15 ml/minute is ___mg twice daily for one week followed by ___mg twice daily for a minimum of 3 months.

• 5, 10

• 10, 5

• 2.5, 5

• 5, 2.5

Eliquis is a brand of Apixaban from _____Company

• Sun

• Lupin

• Pfizer

• Cipla

Reteplase is a tissue plasminogen activator which converts plasminogen into ______which dissolves clot.

• Thrombin

• Fibrin

• Plasmin

• None of these

Reconstitution of Reteplase requires addition of ___ml of sterile water to make a solution which needs to be given as intravenous over ___minutes. After ____minutes, same process is repeated.

• 10, 1, 30

• 10, 2, 30

• 10, 3, 30

• None of these

Ticagrelor is an antiplatelet agent which blocks ______receptors and leads to inhibition of platelet aggregation.

• GpIII2B

• Gp1b5IX

• P2Y12

• P2X12

Recommended bolus dose of Ticagrelor in ACS patients is ___mg followed by ___mg twice daily for 1 year.

• 90, 180

• 180, 90

• 90, 60

• 60, 90